XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...
Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...
Avenzo Therapeutics pays $50M upfront to DualityBio for rights to bispecific antibody-drug conjugate DB-1418. Deal follows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback